DVHGF and GSD Related Headlines
Go Back- Devonian Reports Results of its Annual General and Special Meeting of Shareholders
- Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026
- Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects
- Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls
- Devonian reports additional molecular data from MASH liver study
- Devonian Health shows positive preclinical results for lung fibrosis drug
- DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
- Devonian Health Group names Dennis Turpin as chief financial officer
- DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT
- DEVONIAN ANNOUNCES SHARE CONSOLIDATION IN FURTHER PREPARATION FOR POTENTIAL U.S. LISTING
- Devonian Health Group Announces Grant of Stock Options
- Devonian Health Group Announces Publication of Landmark Study Highlighting Thykamine™ as a Promising New Anti-Inflammatory Agent
- Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member
- Devonian corrects private placement proceeds to $2.4 million
- Devonian Provides Corporate Update and Additional Information Regarding its Previously Announced Private Placement
- Devonian Health Group closes $2.3 million private placement
- Devonian Announces Closing of a Private Placement of Units
- Devonian Health Group Reports Third Quarter 2025 Financial Results
DVHGF and GSD Related Press Releases
Go Back- Devonian Reports Results of its Annual General and Special Meeting of Shareholders
- Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026
- Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects
- Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls
- Devonian reports additional molecular data from MASH liver study
- DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
- DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT
- DEVONIAN ANNOUNCES SHARE CONSOLIDATION IN FURTHER PREPARATION FOR POTENTIAL U.S. LISTING
- Devonian Health Group Announces Grant of Stock Options
- Devonian Health Group Announces Publication of Landmark Study Highlighting Thykamine™ as a Promising New Anti-Inflammatory Agent
- Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member
- Devonian Provides Corporate Update and Additional Information Regarding its Previously Announced Private Placement
- Devonian Announces Closing of a Private Placement of Units
- Devonian Health Group Reports Third Quarter 2025 Financial Results
